In this study, we have shown both in vitro and in vivo that the targeted down-regulation of SOX2 using ATF based technologies can be used as an effective tool for the treatment of SCC in lung and esophageal cancers that express SOX2. The gene discussed is SOX2; the disease is esophageal cancer.